medigraphic.com
ISSN 1561-2937 (Print)

2017, Number 1

<< Back Next >>

Rev Cubana Cardiol Cir Cardiovasc 2017; 23 (1)

Subclinical cardiovascular disease in middle age woman with polycystic ovary syndrome

Carmenate PJV, Monteagudo PG, Peix GA, Quiroz LJJ, Ovies CG, González DN

Language: Spanish
References: 16
Page:
PDF size: 460.98 Kb.


ABSTRACT

Introduction: The relationship between Polycystic Ovarian Syndrome (PCOS) and subclinical cardiovascular disease is not defined.
Objectives: To identify the frequency of subclinical cardiovascular disease in middle-aged women with PCOS and its relation with related factors.
Method: cross-sectional descriptive study, feasibility sampling (60 women), with and without PCOS, 1: 1 distribution. Variables related to demographic data, clinical history, anthropometric, me- tabolic, hormonal and subclinical cardiovascular manifestations by carotid doppler, echocardiogram and ergometric test. Statistical analysis with summary measures and comparisons between groups.
Results: Subclinical cardiovascular alterations were observed in SOP 46.6% vs non-SOP 16.6% (p = 0.012). In SOP vs non-SOP, diastolic dysfunction was detected in 46.6% vs 33.3% (p = 0.249). The carotid intima-media thickness (IMT) was 0.68 mm vs 0.64 mm in the left carotid artery and 0.69 mm in the right side (p = 0.022). The IMT ≥ 0.9 mm was present in 30% vs 6.67% ( P = 0.020). The thickness of epicardial fat ≥ 5 mm (13.3% vs 3.3%, p = 0.161) and the mean was 3 mm vs 1.5 mm (p = 0.006) in PCOS vs non-SOP respectively. Higher values of triglycerides (1.8 vs 1.15 mmol / L, p = 0.0009), insulinemia (12 vs 6.6 mIU / L, p = 0.0014), and glycemia (5.5 vs 4.8 mmol / L, p = 0.0020) Subclinical cardiovascular disease and no relation of this with the phenotype was observed.
Conclusions: In middle-aged women with PCOS, the frequency of subclinical cardiovascular disease increases and is related to metabolic factors.


REFERENCES

  1. Hart R, Hickey M, Franks S. Definitions, prevalence and symptoms of polycystic ovaries and polycystic ovary syndrome. Best Pract Res Clin Obstet Gynecol. 2004; 18:671-683

  2. March WA, Moore VM, Willson KJ, Phillips DI, Norman RJ, Davies MJ. The prevalence of polycystic ovary syn-drome in a community sample assessed under con-trasting diagnostic criteria. Hum Reprod. [revista en la Internet]. 2010 [citado 2014 Jul 16];25:544-551.Disponible en: http://humrep.oxfordjournals.org/content/27/1/14.long

  3. Azziz R, Carmina E. The Androgen Excess and PCOS Society criteria for the POCS: the complete task force report. Fert Steril. 2009,91:456-488.

  4. García García Y. Evaluación de la sensibilidad a la in-sulina en el síndrome de ovario poliquístico. Rev Cuba-na Endocrinol. [revista en la Internet]. 2009 [cita-do 2014 Jul 6]; 20(3):131-140. Disponible en: http://www.bvs.sld.cu/revistas/end/vol20_3_09/end06309.htm

  5. Mani H, Levy MJ, Davies MJ, Morris DH, Gray LJ, Bankart J, et al. Diabetes and cardiovascular events in women with polycystic ovary syndrome: a 20-year re-trospective cohort study. Clin Endocrinol. [revista en la Internet]. 2013 [citado 2014 Jul 6]; 78(6): 26–934. Disponible en: http://onlinelibrary.wiley.com/doi/10.1111/cen.12068/pdf

  6. Moran LJ, Misso ML, Wild RA & Norman RJ. Impaired glucose tolerance, type 2 diabetes and metabolic syn-drome in polycystic ovary syndrome: a systematic re-view and meta-analysis. Hum Reprod Update. [revista en la Internet].2010 [citado 2014 Jul 16];16:347–363.Disponible en: http://humupd.oxfordjournals.org/content/16/4/347.full

  7. García García Y, Monteagudo Peña G, Padrón Durán RS, González Suárez R. Evaluación de las alteraciones lipídicas en el síndrome de ovarios poliquísticos y su relación con la resistencia a la insulina. Rev Cubana Endocrinol [revista en la Internet]. 2010 [citado 2014 Jul 16]; 21(2):145-153. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1561-29532010000200003&lng=es

  8. Burghen GA, Givens JR, Kitabchi AE. Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. J Clin Endocrinol Metab. 1980; 50: 113-116

  9. Yu-Hsun Kao W-CC, Ming-I Hsu, Yi-Jen Chen. Endo-thelial Progenitor Cell Dysfunction in Polycystic Ovary Syndrome: Implications for The Genesis of Cardiovas-cular Diseases. Int J Fertil Steril. [revista en la Internet ]. 2013 [citado 2014 Jul 6]; 6(4): Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3850319/.

  10. Verit FF. High sensitive serum C-reactive protein and its relationship with other cardiovascular risk factors in normoinsulinemic polycystic ovary patients without me-tabolic syndrome. Arch Gynecol Obstet. [revista en la Internet]. 2010 [citado 2014 Jul 16] ;281:1009–14. Disponible en: http://link.springer.com/article/10.1007/s00404-009-1226-6/fulltext.html

  11. Lindholm A, Bixo M, Eliasson M, Hudecova M, Arnadot-tir R, Holte J, Poroma IS. Tissue plasminogen acti-vator and plasminogen activator inhibitor 1 in obese and lean patients with polycystic ovary syndrome. Gy-necol Endocrinol. [revista en la Internet]. 2010 [citado 2014 Jul 16]; 26:743–748. Disponible en: http://informahealthcare.com/doi/full/10.3109/09513590.2010.487592

  12. Kaya C, Pabuccu R, Berker B & Satiroglu H. Plasma interleukin-18 levels are increased in the polycystic ovary syndrome: relationship of carotid intima-media wall thickness and cardiovascular risk factors. Fertility and Sterility. [revista en la Internet]. 2010 [citado 2014 Jul 16]; 93: 1200–1207. Disponible en: http://www.sciencedirect.com/science/article/pii/S001502820804435X

  13. Foltyn W, Strzelczyk J , Marek B , Kajdaniuk D , Siemińska L , Zemczak A et al. Selected markers of endothelial dysfunction in women with polycystic ovary syndrome. Endokrynologia Polska. [revista en la Inter-net]. 2011 [citado 2014 Jul 16]; 62 (3):243-248. Dis-ponible en: http://czasopisma.viamedica.pl/ep/article/download/25270/20099

  14. Chang A, Ayers C, minhajyddin A, Tulika J, Nurenberg P, Lemos James, Wild R, Auchus R. Policystic ovarian syndrome and subclinical atherosclerosis among wom-en of reproductive age in dallas heart study. Clin Endo-crinol(Oxf). [revista en la Internet]. 2011 [citado 2014 Jul 16]; 74 (1): 89-96. Disponible en: http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2265.2010.03907.x/full

  15. Talbott EO, Guzick DS, Sutton-Tyrrell K, et al. Evi-dence for association between polycystic ovary syn-drome and premature carotid atherosclerosis in middle-aged women. Arterioscler Thromb Vasc Biol. 2000; 20(11):2414–2421

  16. Rotterdam ESHRE/ASRM-Sponsored PCOS Consen-sus Workshop Group. Revised 2003 consensus on diagnostic criteria and long term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004; 19: 41–47.




2020     |     www.medigraphic.com